<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774471</url>
  </required_header>
  <id_info>
    <org_study_id>EH20-251</org_study_id>
    <nct_id>NCT04774471</nct_id>
  </id_info>
  <brief_title>Advanced Diffusion Tensor MRI for Breast Cancer</brief_title>
  <official_title>Advanced Diffusion Tensor MRI for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthShore University HealthSystem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the accuracy of the BIT-Motion (Breast Imaging&#xD;
      Tensor-Motion) software with non-contrast MRI scanning to detect breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to answer the question: what is the ability of the BIT-Motion&#xD;
      (Breast Imaging Tensor-Motion) software to detect and discriminate between benign and&#xD;
      malignant breast lesions that are identified on mammogram (MG) and ultrasound (US)&#xD;
      examinations. Women over the age of 18 who have a breast lesion that is seen on MG or US will&#xD;
      be eligible to enroll. Participation in this study will involve one non-invasive non-contrast&#xD;
      MRI scan of the breasts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic diagnosis</measure>
    <time_frame>One month</time_frame>
    <description>MRI scans evaluated with BIT-Motion software will be compared to definitive pathologic diagnosis</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Diseases</condition>
  <arm_group>
    <arm_group_label>Women with breast lesions</arm_group_label>
    <description>Women with an identified breast lesion have a non-invasive non-contrast MRI scan prior to biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Evaluation of BIT-Motion software</intervention_name>
    <description>Software program to discern benign versus malignant breast lesions.</description>
    <arm_group_label>Women with breast lesions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This three-year pilot study will be designed in two parts. The first phase will be a test&#xD;
        phase, in which 10 volunteers (5 healthy volunteers and 5 volunteers with a known breast&#xD;
        mass) will undergo a non-contrast breast MRI with non-fat-saturation T2 weighted imaging&#xD;
        followed by a DTI protocol. The DTI data will be analyzed using the BIT-Motion software.&#xD;
        During this phase, the scan technique and data analysis process will be optimized on the&#xD;
        equipment at NorthShore University Healthsystem.&#xD;
&#xD;
        The second phase will then proceed with an accrual goal of 110 patients, scanning, data&#xD;
        acquisition and analysis. The total accrual for this project is 120 subjects.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  scheduled for ultrasound or stereotactic guided breast biopsy&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  able to tolerate up to 90 minutes in the MRI scanner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Has a medical condition that, in the opinion of the investigator, puts the subject at&#xD;
             significant risk&#xD;
&#xD;
          -  Has any contraindication to the MRI examination as determined by standard NorthShore&#xD;
             University Health System relative to MRI safety&#xD;
&#xD;
          -  Cannot comprehend or complete the Informed Consent Form&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob S Ecanow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Ecanow, MD</last_name>
    <phone>(847) 570-1839</phone>
    <email>JEcanow@northshore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Feczko</last_name>
    <phone>(847) 570-1839</phone>
    <email>CFeczko@northshore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <contact_backup>
      <last_name>Principle Investigator</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem</investigator_affiliation>
    <investigator_full_name>Jacob Ecanow</investigator_full_name>
    <investigator_title>M.D., FPA</investigator_title>
  </responsible_party>
  <keyword>Diffusion Tensor Imaging</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

